Stock news timeline · BIOCON
News timeline · Last 30 days
23 Aug 2026 – 21 Sep 2026 · Times in IST
Showing 16 of 16 updates · Newest first
Change the keyword or sentiment above, then click Apply.
Bank of Baroda plans to divest 35% holding via NSE OFS; Biocon faces a ₹638.4 crore block deal at ₹385/share. TCS wins ₹122.6 crore Odisha govt. contract; Innovision, Enviro Infra secure orders worth ₹243.6 crore, ₹189.99 crore. Source: CNBC TV 18
True North plans to sell Rs 640-cr stake in Biocon via block deal at Rs 385/share, 2% below CMP. Biocon's Q1 profit surged 350%; block deal may cause short-term stock volatility, attracting institutional interest. Source: NDTV Profit
Active Pine plans to sell 1.66 crore Biocon shares, 1% equity. Block deal initiated in Biocon as part of the sale. Source: ScoutQuest
Biocon shares gained 2%, reaching Rs 399 on NSE, after securing a 10-year Pertuzumab supply deal in Brazil. The partnership supports HER2+ breast cancer therapy production and commercialization under Brazil's PDP program. Source: The Economic Times
Biocon secures a 10-year contract with Bahiafarma and Bionovis for Pertuzumab supply in Brazil. The agreement under Brazil's PDP grants exclusive access to 70% of the public healthcare market. Source: BSE
Biocon's U.S. unit gains FDA approval for YESINTEK prefilled autoinjector. YESINTEK autoinjector offers doses of 45 mg 0.5 mL and 90 mg mL. Source: MarketScreener India
Biocon schedules analyst and investor meeting for Sept 4. Focus likely on business performance, strategy, and outlook. Source: Livesquawk
Biocon announces ₹0.50/share final dividend for FY 2025-26. Dividend payment processed electronically for shareholders holding shares by July 3, 2026. Source: ScoutQuest
True North plans to sell Biocon shares worth ₹700 crore, reports NDTV Profit. Source: Livesquawk
Mylan Inc. clarified its disclosure under SEBI regulations, correcting its post-sale shareholding in Biocon Ltd to nil. The sale involved 9.2 crore shares (5.64%), executed via open market on 14 July 2026. Source: BSE
Biocon Ltd received Japan's MHLW approval for its pegfilgrastim biosimilar, developed by Biocon Biologics. Sandoz K.K. will exclusively distribute the product, strengthening Biocon's biosimilar portfolio in Japan. Source: BSE
FTSE's Sept 2026 index review includes 10 Indian stocks, like Infosys, Bharti Airtel, Groww; Biocon to exit. Meesho may see $75.9M inflows; Biocon faces $20M outflows. ETFs likely to rebalance portfolios before Sept. 21. Source: NDTV Profit